Clinical Report: Rayner Expands US Cataract Platform with Anikavisc Acquisition
Overview
Rayner has acquired the US distribution rights to Anikavisc, enhancing its cataract surgery offerings. This acquisition supports Rayner's goal of providing a comprehensive portfolio that includes advanced ophthalmic viscosurgical devices (OVDs) and innovative intraocular lenses (IOLs).
Background
The acquisition of Anikavisc is significant as OVDs play a critical role in cataract surgery by maintaining anterior chamber stability and protecting corneal endothelium. With the increasing demand for efficient and effective cataract solutions, Rayner's expansion into this market is timely. The integration of Anikavisc into Rayner's portfolio aligns with current trends in ophthalmic surgery, emphasizing the importance of comprehensive care.
Data Highlights
No numerical data or trial data was provided in the source material.
Key Findings
- Rayner has acquired the US distribution rights to Anikavisc OVD from Visco Technologies Inc.
- Anikavisc is designed to protect the corneal endothelium and maintain anterior chamber depth during cataract surgery.
- This acquisition allows Rayner to offer a fully bundled cataract solution, simplifying orders and streamlining purchasing.
- Rayner is also launching the FDA-approved Sophi phaco platform and expanding its portfolio with the RayOne EMV Toric IOL.
- The company aims to provide a comprehensive range of solutions, including the upcoming AI-designed RayOne Galaxy IOL.
Clinical Implications
The acquisition of Anikavisc enhances the options available to surgeons, potentially improving surgical outcomes through the use of advanced OVDs. This move may also simplify the purchasing process for healthcare providers, allowing for a more integrated approach to cataract surgery.
Conclusion
Rayner's acquisition of Anikavisc represents a strategic enhancement of its cataract surgery offerings, positioning the company to better meet the needs of healthcare providers and patients alike.
References
- Ophthalmology Management, September 1, 2000 -- Icahn Raids Again
- Optometric Management, October 1, 2000 -- O.D. NOTEBOOK
- Ophthalmology Management, November 1, 2013 -- New Product Report
- Cataract in the Adult Eye Preferred Practice Pattern® - ScienceDirect
- Prospective randomized clinical trial evaluating efficacy and safety of a new ophthalmic viscosurgical device in patients undergoing cataract surgery - PMC
- Retinal Physician — SUBSPECIALTY NEWS: New product launches in laser and surgery, progress on clinical trials in dry AMD, and more.
- Rayner Official Website
- Cataract in the Adult Eye Preferred Practice Pattern® - ScienceDirect
- Prospective randomized clinical trial evaluating efficacy and safety of a new ophthalmic viscosurgical device in patients undergoing cataract surgery - PMC
- Full article: Corneal Outcomes Following Cataract Surgery Using Ophthalmic Viscosurgical Devices Composed of Chondroitin Sulfate-Hyaluronic Acid: A Systematic Review and Meta-Analysis
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
